Last first author paper with Avik Choudhuri and Brian Abraham ⁦Brian J. Abraham⁩ . From the best lab and the best mentor ⁦Dr. Len Zon⁩ Signaling matters!! nature.com/articles/s4158…

A postdoctoral research associate position is available in the Computational Biology lab of Brian J. Abraham focused on gene expression-regulation mechanisms in healthy and diseased cells. Learn more and share. ow.ly/kVtu50CH4lh #postdoc

Join us for our first “The Science of Childhood Cancer” virtual lecture as Dr. Jinghui Zhang of St. Jude speaks on “Genomic Variants in Pediatric Cancer: Landscape, Precision Oncology, and Data Sharing Ecosystem” Thurs, Jan 28 at noon CT/5 pm CMT. ow.ly/8vBW50DfTO7 #SOCC21

To paraphrase Daria, there is no science that can't be improved with a group coffee.

Join us July 22-23 for the virtual Bringing Chemistry to Medicine Symposium featuring thought leaders in areas spanning therapeutic regulation of transcription & chromatin, computational biology, and chemical biology. View speakers: ow.ly/661u50FbTSP #TranscriptionTherapy

Open staff #compbio #bioinformatics position in the Abraham Lab at St. Jude Research. We study chromatin makeup and organization in a variety of cancer types. Apply here: careers-stjude.icims.com/jobs/7446/bioi…

As a physician, scientist and president and CEO of St. Jude, Dr. James R. Downing speaks up for evidence-based medicine, science and the future of children. Read his new op-ed. ow.ly/JNuY50FYNPd #GetVaccinated #WearAMask @dailymemphian

Cancer patients with high-risk neuroblastoma often benefit from retinoic acid treatment. Read latest on how the drug works and what that means for the future of cancer treatment. ow.ly/FiOQ50GuM76 Science Advances Brian J. Abraham

Join us! St. Jude is recruiting multiple research faculty at the full, associate, and assistant levels in a major expansion of our basic and translational research programs. #cancerresearch #facultyjobs @stjuderesearch stjude.org/cancer-center-…

New paper out from our lab investigating the use of the putative RNA-POL I inhibitor CX-5461 in pediatric neuroblastoma. I believe this study represents a fantastic example of why the details of drug mechanism are deeply important for patient safety. nature.com/articles/s4146…

Another foothold into drugging transcription shows that it matters in neuroblastomas. Strong collaboration among Adam Durbin Jun Qi Lab Stegmaier Lab and many other friends.

Deeply #thankful for strong, clever collaborators who like to tackle important problems, like this team. It made and makes sense for transcription factors that drive specific cancer types to be expressed only in those cancer types. @lawrensonlab built a way to find them.

Analyzing sequencing data can be hard, especially if you don't have a seasoned analyst or heavy-duty hardware. So Modupe built a portable, modular, automated, cloud (and more) pipeline to do the most common ChIP-Seq/CUT&RUN-Seq analyses for about $20 per sample.

Pleased that our review on cell state plasticity and core regulatory circuitry online! Check it out! Thanks to Cell Reports Medicine, including Isabel Goldman and Sara Hamilton for their support!. Brian J. Abraham Mark Zimmerman. #neuroblastoma #epigenetics cell.com/cell-reports-m…

Join the faculty of St. Jude Research as we continue our major research/translational expansion. All levels, expansive scientific foci considered. More information here: stjude.org/cancer-center-…

Our massive undertaking in finding vulnerabilities of pediatric cancers requires massive #bioinformatics talent. I'm excited to be a part of the team and am looking for scientists to join the effort. Posting forthcoming, but feel free to email your CV.

St. Jude is seeking its next generation of graduate students. These students are exposed to the undersold breadth of research on campus and given tremendous resources to lead their own impactful research.

I don't know that I've seen a project that ended so far and so much more important than the OG plan. From feelings that something is weird about CDK13 to battling the lack of reagents to separate it from CDK12 to tying stumbling polymerases to cancers. Big work; long time coming.